Posted On: 12/04/2014 8:23:41 AM
Post# of 30066
I could see being concerned if the company said they were going to be able to cure Wolfram syndrome or Diabetes by December and sales were going to be a $1B and JN said they were only going to be $1M, but all the company said is we're licensing MANF related IP from UofM and entered into a collaboration with WU.
Not every collaboration or license agreement will turn into blockbuster opportunity. All you need is one.
Wolfram
Dec. 18, 2013 - Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
June 20, 2014 - Amarantus entered into research collaboration with the Washington University School of Medicine
http://investorshangout.com/post/view?id=2201...z3KvzkrWTl
Not every collaboration or license agreement will turn into blockbuster opportunity. All you need is one.
Wolfram
Dec. 18, 2013 - Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
June 20, 2014 - Amarantus entered into research collaboration with the Washington University School of Medicine
http://investorshangout.com/post/view?id=2201...z3KvzkrWTl
(0)
(0)
